| ATM mutations in cancer: therapeutic implications M Choi, T Kipps, R Kurzrock Molecular cancer therapeutics 15 (8), 1781-1791, 2016 | 461 | 2016 |
| Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells D Lu, MY Choi, J Yu, JE Castro, TJ Kipps, DA Carson Proceedings of the National Academy of Sciences 108 (32), 13253-13257, 2011 | 451 | 2011 |
| Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial JA Jones, AR Mato, WG Wierda, MS Davids, M Choi, BD Cheson, ... The lancet oncology 19 (1), 65-75, 2018 | 427 | 2018 |
| Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study JF Seymour, S Ma, DM Brander, MY Choi, J Barrientos, MS Davids, ... The Lancet Oncology 18 (2), 230-240, 2017 | 388 | 2017 |
| Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy S Coutre, M Choi, RR Furman, H Eradat, L Heffner, JA Jones, B Chyla, ... Blood, The Journal of the American Society of Hematology 131 (15), 1704-1711, 2018 | 170 | 2018 |
| Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia MY Choi, GF Widhopf, EM Ghia, RL Kidwell, MK Hasan, J Yu, LZ Rassenti, ... Cell Stem Cell 22 (6), 951-959. e3, 2018 | 158 | 2018 |
| Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1 MY Choi, GF Widhopf II, CCN Wu, B Cui, F Lao, A Sadarangani, ... Clinical Lymphoma Myeloma and Leukemia 15, S167-S169, 2015 | 134 | 2015 |
| Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 116 | 2020 |
| AGS67E, an anti-CD37 monomethyl auristatin E antibody–drug conjugate as a potential therapeutic for B/T-cell malignancies and AML: a new role for CD37 in AML DS Pereira, CI Guevara, L Jin, N Mbong, A Verlinsky, SJ Hsu, H Aviña, ... Molecular cancer therapeutics 14 (7), 1650-1660, 2015 | 96 | 2015 |
| Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib J Yu, L Chen, B Cui, C Wu, MY Choi, Y Chen, L Zhang, LZ Rassenti, ... Leukemia 31 (6), 1333-1339, 2017 | 90 | 2017 |
| Ulocuplumab (BMS-936564/MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway MK Kashyap, D Kumar, H Jones, CI Amaya-Chanaga, MY Choi, ... Oncotarget 7 (3), 2809, 2016 | 89 | 2016 |
| Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib J Jones, MY Choi, AR Mato, RR Furman, MS Davids, LT Heffner, ... Blood 128 (22), 637, 2016 | 83 | 2016 |
| Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib MJ Gordon, M Churnetski, H Alqahtani, X Rivera, A Kittai, SM Amrock, ... Cancer 124 (15), 3192-3200, 2018 | 81 | 2018 |
| Inhibitors of B-cell receptor signaling for patients with B-cell malignancies MY Choi, TJ Kipps The Cancer Journal 18 (5), 404-410, 2012 | 63 | 2012 |
| NCCN guidelines insights: T-cell lymphomas, version 2.2018 SM Horwitz, SM Ansell, WZ Ai, J Barnes, SK Barta, M Choi, MW Clemens, ... Journal of the National Comprehensive Cancer Network 16 (2), 123-135, 2018 | 61 | 2018 |
| Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia Y Chen, L Chen, J Yu, EM Ghia, MY Choi, L Zhang, S Zhang, ... Blood, The Journal of the American Society of Hematology 134 (13), 1084-1094, 2019 | 57 | 2019 |
| Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia MK Kashyap, CI Amaya-Chanaga, D Kumar, B Simmons, N Huser, Y Gu, ... Journal of hematology & oncology 10, 1-16, 2017 | 54 | 2017 |
| Deep and durable responses following venetoclax (ABT-199/GDC-0199) combined with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia: results from a … S Ma, DM Brander, JF Seymour, TJ Kipps, JC Barrientos, MS Davids, ... Blood 126 (23), 830, 2015 | 54 | 2015 |
| The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor MY Choi, MK Kashyap, D Kumar Best practice & research Clinical haematology 29 (1), 40-53, 2016 | 53 | 2016 |
| Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers ML Wang, JC Barrientos, RR Furman, M Mei, PM Barr, MY Choi, S de Vos, ... NEJM evidence 1 (1), EVIDoa2100001, 2022 | 50 | 2022 |
Thomas J. KippsProfessor of Medicine, UC San Diego在 ucsd.edu 的电子邮件经过验证
